Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Total Non-Current Liabilities (2021 - 2025)

Historic Total Non-Current Liabilities for Neuphoria Therapeutics (NEUP) over the last 5 years, with Q4 2025 value amounting to $4.2 million.

  • Neuphoria Therapeutics' Total Non-Current Liabilities rose 1591.63% to $4.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.2 million, marking a year-over-year increase of 1591.63%. This contributed to the annual value of $5.9 million for FY2025, which is N/A changed from last year.
  • Per Neuphoria Therapeutics' latest filing, its Total Non-Current Liabilities stood at $4.2 million for Q4 2025, which was up 1591.63% from $6.7 million recorded in Q3 2025.
  • Neuphoria Therapeutics' 5-year Total Non-Current Liabilities high stood at $6.7 million for Q3 2025, and its period low was $2.8 million during Q1 2025.
  • Over the past 5 years, Neuphoria Therapeutics' median Total Non-Current Liabilities value was $3.8 million (recorded in 2023), while the average stood at $4.2 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 598.98% in 2023, then skyrocketed by 6224.05% in 2025.
  • Quarter analysis of 5 years shows Neuphoria Therapeutics' Total Non-Current Liabilities stood at $3.1 million in 2021, then rose by 16.72% to $3.6 million in 2022, then increased by 5.99% to $3.8 million in 2023, then fell by 5.68% to $3.6 million in 2024, then grew by 15.92% to $4.2 million in 2025.
  • Its Total Non-Current Liabilities was $4.2 million in Q4 2025, compared to $6.7 million in Q3 2025 and $5.9 million in Q2 2025.